Cosentyx (secukinumab)

Cosentyx (secukinumab) is indicated for the treatment of adults with:

  • Moderate to severe plaque psoriasis.
  • Active psoriatic arthritis (PsA).
  • Active ankylosing spondylitis (AS).

This medicine is not (yet) part of our standard product range but we may be able to get it for you. The packaging size and strength below may vary due to product availability. Please contact us to verify price and availability.

  • Disease Indications : Psoriatic Arthritis
  • Manufacturer: Novartis
  • Usage : Subcutaneous
Medicine approved by
  • European Medical Agency (EMA)
  • Food and Drug Administration (FDA)
  • Health Canada
  • Therapeutic Goods Administration (TGA)
  • Medsafe (NZ)